Disease Domain | Count |
---|---|
Nervous System Diseases | 8 |
Neoplasms | 2 |
Endocrinology and Metabolic Disease | 2 |
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 10 |
Chemical drugs | 1 |
Microbiota | 1 |
Synthetic peptide | 1 |
Colony-stimulating factors | 1 |
Target |
Mechanism EPO receptor agonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CD82 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Cell replacements |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Oct 2025 |
Sponsor / Collaborator ![]() [+1] |
Start Date28 May 2025 |
Sponsor / Collaborator [+5] |
Start Date12 May 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Recombinant human erythropoietin(Hanyang University) ( EPO receptor ) | Amyotrophic Lateral Sclerosis More | Phase 2 |
rCT-S100A8/A9 ( MOK x TLR4 ) | Colorectal Cancer More | Preclinical |
Mesenchymal stem cell therapy (Hanyang University/SCM Lifescience) | Diabetic Foot More | Preclinical |
Compound 32e(Hanyang University) ( CCNK x CDK12 ) | HER2 Positive Breast Cancer More | Preclinical |
Compound 22b(Hanyang University) ( JNK3 ) | Alzheimer Disease More | Preclinical |